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Abstract
Background: Central Sensitization (CS) involves dysfunction in neurophysiological mechanisms that increase
neuronal responses to both noxious and non-noxious stimuli in the central nervous system. The Central
Sensitization Inventory (CSI) is considered the leading patient-reported outcome measure for assessing CS-related
symptoms. The aim of this study was to translate and cross-culturally adapt the CSI into Finnish (CSI-FI) and to
evaluate its psychometric properties.
Methods: Translation and cross-cultural validation of the CSI was conducted according to established guidelines.
The validation sample was 229 subjects, including 42 pain free controls and 187 subjects with chronic
musculoskeletal pain. The CSI-FI was evaluated for internal consistency, test-retest reliability, exploratory factor
analysis with maximum likelihood extraction, relationship with subject-reported outcome measures [Tampa scale of
kinesiophobia (TSK), the Depression scale (DEPS), 5-level EQ-5D version (EQ-5 L-5D), Roland-Morris Disability
Questionnaire (RMDQ), and Pain and Sleep Questionnaire Three-Item Index (PSQ-3)], pain history, subjective
symptoms of dizziness, and CS-related diagnoses on CSI part B. Furthermore, we studied the ability of the CSI-FI to
distinguish pain free controls, subjects with chronic pain in a single body area, and subjects with multisite chronic
pain. In addition, we studied the relationship of CSI-FI scores with postural control on a force plate.
Results: The CSI-FI demonstrated good internal consistency (0.884) and excellent test-retest reliability (0.933) with a
7 ± 1 day gap between test administrations. Exploratory factor analysis with maximum likelihood extraction yielded
a one factor solution. Fair to good correlations were found between the CSI-FI and the TSK, DEPS, EQ-5 L-5D,
RMDQ, and PSQ-3. Subjective symptoms of dizziness correlated better with CSI-FI scores than any of the CS-related
diagnoses on CSI part B. Total CSI-FI scores successfully distinguished between pain free controls, subjects with
chronic pain in a single body area, and subjects with multisite chronic pain. The multisite pain group reported
significantly more dizziness symptoms than the other two groups. Force plate measurements showed no
relationship between postural control and CSI-FI scores.
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Conclusion: The CSI-FI translation was successfully cross-culturally adapted and validated into Finnish. CSI-FI
psychometric properties and scores were all in acceptable levels and in line with previous CSI validations. The CSI-FI
appears to be a valid and reliable instrument for assessing CS-related symptomology in Finnish-speaking
populations.
Keywords: Central sensitization, Central sensitization inventory, Psychometric validation, Musculoskeletal pain,
Chronic pain, Low back pain, Dizziness, Postural control
Background
Central sensitization (CS) involves dysfunction in neuro-
physiological mechanisms that increase neuronal re-
sponses to both noxious and non-noxious stimuli in the
central nervous system [1]. It was originally defined by
Woolf et al. 2011 as “an amplification of neural signal-
ling within the central nervous system that elicits pain
hypersensitivity” [2]. Underlying factors contributing to
the CS phenomenon are complex, individualised, and
not well understood [3].
The most common clinical signs and symptoms for
CS-related pain syndromes include increased sensitivity
to stimuli, lowered pain stimulus threshold, and pro-
longed pain after the stimulus has been removed [4].
Neurophysiological mechanisms of CS, with enhanced
neuronal responses to stimuli, can contribute to pro-
longed symptoms in a wide variety of disorders. The
term central sensitivity syndromes (CSSs) has been pro-
posed to describe syndromes related to CS [5]. Pain is a
predominant symptom in many CSSs, like fibromyalgia
and irritable bowel syndrome. However, in some CSSs,
like chronic fatigue syndrome or restless leg syndrome,
pain is a secondary or non-significant symptom. CS can
also contribute to trauma-related multidimensional
symptomology, such as with whiplash syndrome [5, 6].
CS is one underlying multidimensional biopsychoso-
cial factor leading to chronic pain [7]. Chronic musculo-
skeletal pain has been found to be associated with
postural control instability compared to healthy controls
[8, 9]. Postural control is a term used to describe regula-
tion of the nervous system in order to produce and
maintain a controlled, upright posture [10]. Instable pos-
tural control is one of the first signs and symptoms of
many neurological diseases and cognitive impairments
[11, 12] and is evident in fibromyalgia, which is a well-
established CS-related pain syndrome [13, 14]. Subject-
ive dizziness, vertigo and unsteadiness are also common
symptoms of fibromyalgia [15–17].
The Central Sensitization Inventory (CSI) was devel-
oped in 2012 for clinical use to screen patients for symp-
toms related to CS and CSS [18]. The CSI is considered
the leading patient-reported outcome measure (PROM)
for assessing CS-related symptomology [19]. Although it
has a short, less than ten year history, the CSI has been
translated and validated in adult populations into many
languages, including Dutch [20], Spanish [21], Brazilian
Portuguese [22], Gurajati [23], Serbian [24], French [25],
Japanese [26], Greek [27], Nepalese [28], Russian [29], and
Italian [30]. Additionally, the CSI has been validated in an
adolescent population in European Portuguese [31]. Pub-
lished results from previous cultural adaptations and vali-
dations suggest that the CSI is a reliable, valid, and
consistent measure [32]. Previous studies have shown
good discriminative ability of the CSI to distinguish be-
tween chronic pain subjects and control subjects without
pain [32–34]. Associations have been found between CSI
scores and other validated patient-reported measures of
CS-related symptoms, including depression symptoms,
kinesiophobia, perceived disability, health-related quality
of life, and sleep problems [26, 27, 30, 33]
Due to rationale linking chronic pain syndromes and
fibromyalgia with postural control instability, it was hy-
pothesized that there may be a potential relationship be-
tween higher CSI scores and postural control instability
on a force plate. The force plate is mechanical sensing
systems designed to measure the ground reaction forces
and moments involved in postural control [36]. We also
hypothesised that CSI scores may correlate with subject-
ive dizziness symptoms. As far as we know, the relation-
ships between CSI scores, postural control, and dizziness
symptoms have not been researched previously.
The aim of this validation was to translate and cross-
culturally adapt the CSI into Finnish and to evaluate its
reliability (Internal consistency, test-retest reliability and
measurement error), psychometric properties (relation-
ship with other patient reported outcome measures), fac-
tor analysis (exploratory factor analysis with maximum
likelihood extraction), and relationships between pos-
tural control on a force plate and subjective symptoms
of dizziness. We also studied the discriminative ability of
the CSI-FI with three subgroups: 1. Pain free controls, 2.
Chronic pain in a single body area, and 3. Chronic mul-
tisite pain (pain in two or more body areas). This
validation study adhered, where applicable, to the
COonsensus-based Standards for the selection of health
Measurement INstruments (COSMIN) checklist for
methodological quality of studies on measurement prop-
erties of instruments [37].
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Methods
Ethical approval and consent to participate
Ethical approval for the study was obtained from the Re-
search Ethics Committee of the Northern Savo Hospital
District with identification number 1106/13.02.00/2018.
Written informed consent was obtained from all subjects
prior to the study. The study was conducted in accord-
ance with the declaration of Helsinki.
Study subjects
Study subjects were recruited through advertisements on
the webpage of the Chiropractic private practice where
the study was conducted and on other web pages and
social media via different national Finnish musculoskel-
etal pain and spine-related organizations and healthcare
colleagues. All 18–65 years old subjects meeting inclu-
sion criteria for the study from the general population
were invited to participate, whether they suffered pain or
not. Inclusion criteria for the study were: 1) Age be-
tween 18 and 65 years 2) Proficient in written and
spoken Finnish language. Exclusion criteria for the study
were: 1) History of malignant tumour 2) History of diag-
nosed trauma or disease negatively affecting the central
nervous system, including multiple sclerosis, Alzheimer’s
disease, and dementia. A total of 257 subjects agreed to
participate and booked clinical appointments through an
online booking system. Three subjects were excluded be-
cause they did not complete the study questionnaires as
instructed during the clinical appointments. Five add-
itional subjects were excluded because of clear signs and
symptoms indicating undiagnosed neurological patho-
logical conditions affecting the central nervous system.
After the exclusions, the total number of participants in
the study was 249. Twenty of those participants were
used only for feedback about the face validity of the
Finnish translation of the CSI, and 229 subjects were
used for the psychometric validation portion of the
study. See the flow chart of subjects in Fig. 1.
Translation and cross-cultural adaptation of the CSI
Translation and cross-cultural validation of the CSI from
English into Finnish was conducted using standard
guidelines, including a forward-backward translation
method [35]. The multidisciplinary research group who
authored this study included a chiropractor with post
graduate qualifications in clinical neurology, Professor of
Physiotherapy, Professor of Physical and Rehabilitation
Medicine, licensed mental health professional and Pro-
fessor of Neurosurgery. All these authors had more than
ten years of clinical experience and expertise in chronic
pain conditions and treatment.
First, permission to translate the CSI into Finnish was
obtained from one of the original authors of CSI (author
RN). After written permission was granted, the initial
translation was made by the first author (JM) and a pro-
fessional translator from English into Finnish. Both are
native Finnish speakers and were blinded from each
other’s translation. The first author has completed his
undergraduate and post-graduate degrees in English
speaking countries and the professional translator was a
specialist in medical and related healthcare field texts.
Then second (HL) and last author (VL) formed an ex-
pert panel, independently reviewed the initial transla-
tions, chose the most appropriate translated items and
provided comments and suggestions for changes to one
item. All comments and suggestions were discussed with
the first author. One translation problem was identified
in item number 24 concerning childhood trauma. A dir-
ect Finnish translation of the option “always” was found
to be obscure in the context of this item, so it was modi-
fied into a more appropriate Finnish word, which
roughly translates to “frequently” in English. Also, some
minor wording changes in content were made. A second
professional translator and native English speaker, who
was naïve to the CSI and purpose of this study, and who
was also fluent in Finnish, created a backtranslation. The
back translation was checked and approved by author
RN, a native English-speaker.
Finally, the provisional CSI-FI was tested for face val-
idity in twenty subjects. All subjects were informed
about the details of the study and asked to give non-
structured written or verbal feedback about their com-
prehension of each item on the questionnaire. All feed-
back about item comprehension was positive and all
subjects were able to complete the CSI-FI without diffi-
culty. Thus, the final version of the CSI-FI was estab-
lished. Translated versions of the CSI, including the
English and Finnish versions, can be found at https://
www.pridedallas.com/questionnaires/.
Data collection
Data were collected from May 2019 until March 2020 in
a single Chiropractic private practice setting. The object-
ive clinical measurements of postural control with a
force plate and a structured interview assessing symp-
toms and history of dizziness during the past 12 months
were collected during the clinic visit. After the clinic
visit, subjects were asked to complete an online web-
based battery of demographic information (age, gender,
height, weight, and pain history) and clinical question-
naires at home, including the CSI-FI. Body mass index
was calculated in the data analysis phase from subject-
reported height and weight data. Subjects were then in-
vited by email to complete the CSI-FI a second time 7 ±
1 days later for the purpose test-retest reliability assess-
ment. The minimum number of subjects required for
the test-retest evaluation was determined by previous
CSI cultural adaptations and validations [18, 20, 26].
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After one-hundred CSI-FI questionnaires were col-
lected, no more email invitations were sent. All test-
retest participants were asked to avoid starting any
new types of pain medication and/or physical treat-
ment, when ethically possible, during 7 ± 1-day gap
between test administrations.
Subject-reported pain history questions
Each subject completed a structured web-based pain his-
tory, which asked dichotomous questions, including:
chronic low back pain yes/no; referral to leg or leg pain
yes/no (if yes to chronic low back); other chronic
musculoskeletal pain yes/no; chronic headache yes/no;
history of rheumatic disease diagnosed previously by
physician yes/on. Subjects were also asked to rate pain
severity on a numerical pain scale from 0 to 10 and to
indicate pain duration in number of months with pain.
Subject-reported clinical outcome measures
The numerical pain rating scale (NPRS) is an eleven-
point numerical scale. The scale is composed of 0 (no
pain at all) to 10 (worst imaginable pain) and pain dur-
ation in months [38]. Chronic pain was defined as more
than 3 months and more than 3 days per week.
The CSI is a two-part questionnaire [18]. Part A in-
cludes 25 questions about CS-related symptomology.
The total score range is “0” to “100.” Higher scores indi-
cate a higher number and frequency of CS-related symp-
toms. Frequency of symptoms is rated with the following
in Likert scale options: 0 = never, 1 = rarely, 2 = some-
times, 3 = often, and 4 = always. Recommended clinical
severity scores are: subclinical = 0 to 29; mild 30–39;
moderate 40–49; severe = 50–59; and extreme = 60 to
100 [6, 39]. A recommended cut-off score for indicating
clinically significant CS-related symptomology is 40 [6].
Part B asks with “No/Yes, and year diagnosed” about 7
Fig. 1 Flow chart of subjects
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possible previously diagnosed CSSs (Restless Leg
Syndrome, Chronic Fatigue syndrome, Fibromyalgia,
Temporomandibular Joint Disorder, Migraine or tension
headaches, Irritable Bowel Syndrome, and Multiple
Chemical Sensitivities) and 3 CS-related disorders (Neck
injury including whiplash), Anxiety or panic attacks, and
Depression). CSI B part is only for information and is
not scored [6, 18, 39].
The Tampa scale of Kinesiophobia (TSK) is a 17-item
questionnaire used to assess subjective kinesiophobia
(fear of movement) [40]. The range of scores is from 17
to 68. Higher scores indicate an increasing degree of
kinesiophobia. Items 4, 8, 12 and 16 are reverse-scored.
Agreement with each item is rated with the following
options: 1 = strongly disagree 2 = disagree 3 = agree 4 =
strongly agree [40]. TSK has been translated into Finnish
and validated in a Finnish population [40, 41].
The Depression Scale (DEPS) is widely used and
well-validated 10-item questionnaire used to assess
depressive symptoms. It has a score range between 0
and 30 [42]. Item responses are scored from 0 to 3
on four-point Likert scale options: 0 = not at all, 1 = a
little, 2 = quite a lot and 3 = extremely. Higher scores
indicate a higher possibility of a Major Depressive
Disorder diagnosis. The DEPS has excellent structural
validity for screening depressive symptoms among pa-
tients with low back pain [43].
Health related quality of life was measured with the
Finnish translation of the 5-level EQ-5D version of the
EuroQol (EQ-5D-5L) [44]. The questionnaire provides a
simple descriptive profile of a respondent’s health status.
The EQ-5D-5L questionnaire consists of five dimen-
sions: mobility, self-care, usual activities, pain/discom-
fort, and anxiety / depression. Each dimension has five
response levels: 0 = no problems, 1 = slight problems,
2 =moderate problems, 3 = severe problems, 4 = unable
to /extreme problems. A second part of the EQ-5D-5L is
the EQ visual analogue scale (EQ VAS). It records the
respondent’s overall current health on a vertical visual
analogue scale, where the endpoints are labelled ‘The
best health you can imagine’ and ‘The worst health you
can imagine’. The EQ-5D-5L and EQ VAS provide a
quantitative measure of one’s overall health state [44].
EQ-5D-5L is scored from 0 = being dead to 1 = being in
full health. An index value calculator was used to calcu-
late a value between 0 and 1. Because there is currently
no Finland standard value set available, a value set from
Denmark was used to calculate the index value as rec-
ommended by the EuroQol EQ-5D-5L User Guide [45].
The Roland Morris Disability Questionnaire (RMDQ)
is a well-validated 24-item questionnaire of disability in
chronic low back pain populations [46]. The RMDQ is
scored by adding up the number of items checked “yes”
on different low back pain-related daily activity
disabilities. Total scores range from 0 to 24, with higher
scores indicating a higher level of disability related to
low back pain [46, 47].
The Pain and Sleep Questionnaire Three-Item Index
(PSQ-3) is a three-item sleep questionnaire designed to
measure the impact of chronic pain on sleep during the
past week [48]. The three questions are: “1. How often
have you had trouble falling asleep because of pain?”, “2.
How often have you been awakened by pain during the
night?”,“3. How often have you been awakened by pain
in the morning?”. These items were translated into
Finnish for the present study. The original PSQ-3 used a
visual analogue scale between 0 to 100 mm. However,
we used a numerical eleven-point rating scale (NRS)
from 0 to 10 in our version. This modification was made
because of the difficulty in creating a visual analogue
scale measurement in a universal digital format. In both
versions, 0 indicates “never” and 100 mm or numerical
scale 10 indicates “always.” Thus, the final score in our
modified version ranged from 0 to 30 instead of 0–300.
Clinical tests of postural control on the force plate
Postural control was measured with a force plate. Be-
cause, the subjects completed the questionnaires after
the clinic visit, the assessor was blinded from the partici-
pants’ pain histories and questionnaire scores. Postural
control measurements included area and velocity of cen-
ter of pressure (COP) displacement, which are the most
commonly used parameters for postural control in
chronic pain syndrome samples in previous studies [36,
49]. COP area and velocity describes the neuromuscular
response to shifts in the body’s center of mass measured
on the balance platform [50].
The postural control tests were carried out in the same
room with identical conditions for each subject, includ-
ing distance to the opposite wall and light on the room.
COP displacement was assessed by a four-channel
portable computerized force plate (BT4; HUR Labs Oy,
Tampere, Finland). The force plate was calibrated prior
to each individual’s measurement. Subjects were
instructed with standardized instructions: to stand bare-
foot, feet as close together as comfortably as possible. If
subjects found this foot stance unnatural, they were
instructed to bring their feet further apart to create a
more stable and natural-feeling standing stance. Subjects
were instructed to look straight ahead and keep balan-
cing in a relaxed manner. They were also instructed to
keep their arms at their sides in a relaxed position.
There was no clear fixation point for gaze, and the op-
posite wall was more than three metres away.
Four different postural control tests were carried out.
Each test was 60 s, which was identical to the time meas-
urement in previous studies on CLBP patients with a
similar testing protocol [49]. A five second pre-phase
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period occurred before the actual COP measurement of
60 s. The sampling frequency was set to 50 Hz, which
was recommended by the manufacturer to balance con-
sistent data acquisition and manageable data size. The
Hurlabs BT4 force plate has a sensitivity of 2,V/V + -
0.25% and an acceptable combined error maximum of
0.03%. Four COP displacement quiet stance measure-
ments in respective order were: eyes open on a stable
surface, eyes closed on a stable surface, eyes open on an
unstable foam surface, eyes closed on an unstable foam
surface. All measurements were carried out once, in
similar (non-randomized) order, and there was no desig-
nated resting period between tests. A rectangular high
density (50 kg/m3) closed-cell Airex Balance Pad (deliv-
ered by manufacturer with the force plate) was used for
all tests requiring a foam surface in order to provide an
unstable surface.
Subject subgroups
The 229 subject group was divided into different sub-
samples for various analyses. To test for postural control
on the force plate, the chronic pain subjects (N = 187)
were divided into two groups according to the recom-
mended cut off score ≥ 40 for indicating clinically signifi-
cant CS-related symptomology [6]. Of these 187
subjects, 117 (62.6%) scored below 40 and 70 (37.4%)
scored above 40. Because we were only interested in
assessing the relationship between CSI scores and pos-
tural control in subjects with chronic pain, pain-free
control subjects were not included in this analysis.
To test for discriminative validity of the CSI-FI, the
total subject sample was divided into three subgroups
based upon self-reported pain symptoms, including pain
free controls, single body area pain, and multisite
chronic pain. Of the 229 total sample 42 (18.7%) re-
ported no pain and were categorized as a control group.
Specifically, the pain-free control subjects reported no
CLBP, no radicular pain, pain scale 0/10, pain history 0
months, no other chronic musculoskeletal pain, and no
chronic headaches. The rest of the sample (187; 81.3%)
reported chronic pain. No subjects reported any acute or
subacute pain. Of the 187 chronic pain subjects, 79
(34%) reported pain in a single body area (CLBP group
with or without leg referral or other chronic musculo-
skeletal pain or chronic headache) and 108 (47%) re-
ported multisite chronic pain (two or more of the
following: CLBP with or without radiculopathy, other
chronic musculoskeletal pain and/or chronic headache).
Subjective dizziness structured interview
A structured interview was done during the clinic visit
about subjects’ dizziness history during the past 12
months. The questions for all subjects were:” Have you
suffered dizziness during last 12 months? Dizziness
means abnormal sensation causing disability for more
than one day, which is not same as normal brief light
headedness when standing up quickly”. Those subjects
who reported dizziness which has resulted in any disabil-
ity lasting more than one day (n = 53; 23%) were inter-
viewed further about dizziness symptom subtypes.
Dizziness subtypes were classified into seven classifica-
tions: 1. off balance or unsteadiness (N = 6), 2. light
headedness (N = 12), 3. Feeling as if passing out (N = 8),
4. spinning or vertigo (N = 6), 5. floating or tilting sensa-
tion (N = 17), 6. blurring of vision when moving the head
(N = 3) or other type (N = 0). This twelve-month time
period of interest and symptom classification followed
recent literature, which is based on symptoms and not
actual diagnosis of any specific vestibular or neuro mus-
culoskeletal condition [51].
Statistical methods
Statistical analysis was performed using the SPSS version
25 (IBM SPSS Statistics for Windows, Version 25.0.
Armonk, NY:IBM Corp.). Statistical significance was de-
fined as p < 0.05. Data were shown as percentages or
means with standard deviations. Group comparisons for
normally distributed variables were executed by inde-
pendent samples t-test or One-Way ANOVA model and
for skewed distributed by Mann-Whitney U-test or
Kruskall-Wallis test. Normality were checked by
Shapiro-Wilks test. Categorical variables were compared
by Chi-square or Fisher’s exact tests.
Cronbach’s Alpha was used to assess internal
consistency. An Alpha value between 0.70 and 0.90 was
considered good, and higher than 0.90 was considered
excellent. Test-retest reliability was calculated by Intra-
class correlation coefficient (ICC) from the second CSI-
FI administration 7 ± 1 days later. ICC values ≤0.40 were
considered to indicate fair reliability, 0.41–0.60 moderate
reliability, 0.61–0.80 substantial reliability, and ≥ 0.81 ex-
cellent reliability. ICC with 95% Confidence Interval (CI)
Lower-and Upper Bound were calculated for each item.
Standard error of measurement (SEM) was calculated
with formula: standard deviation*square root (1-ICC),
where SD = standard deviation of change of CSI-FI
scores from baseline to second administration.
A Kaiser-Meyer-Olkin measure and Bartlett’s Test of
Sphericity were used to test for appropriateness of the
factor analysis. Exploratory factor analysis (EFA) with
maximum likelihood extraction were performed with the
similar requirements for extraction as in a recent pooled
multicountry CSI sample [19] The requirements for ex-
traction were Kaiser criterion for components with Ei-
genvalues > 1.0 and the ratio of the Eigenvalue of the
first and second unrotated component > 4.0. Inflection
point on Cattel scree plot was used to observe similar
finding on the graph [52, 53]. The item loading cut off
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value was set at 0.3. If the loading value was less than
0.3, the item was not retained as a factor.
Spearman’s correlation coefficients were used to in-
vestigate convergent validity of the CSI-FI by calculat-
ing the associations between total CSI-FI scores and
scores on the NPRS, TSK, DEPS, EQ-5D-5L, RMDQ,
PSQ-3 and dizziness history questions. Strengths of
the associations were interpreted as: little or no cor-
relation (< 0.25), fair correlation (0.25 > Rs ≤ 0.50),
moderate to good correlation (0.50 > Rs2 ≤ 0.75), and
good to excellent (Rs > 0.75).
Results
There were no missing subject-reported data. Data col-
lection with the online questionnaires reminded auto-
matically if there were any missing items. Also, no
subjects had a CSI-FI score of zero or of 100 so there
were no data floor or ceiling effects.
Total CSI-FI score distribution and demographic group
differences between the chronic pain and pain-free
control groups
The mean CSI-FI score in the total sample (N = 229)
was 35.3 ± 12.2 with a CSI-FI score range from 11 to 70.
The mean CSI-FI score in the pain-free control group
(N = 42) was 28.0 ± 10.7 with CSI-FI score range from 12
to 43 and in the chronic pain group (N = 187) was
37.0 ± 12.0 with CSI-FI score range from 11 to 70. The
total sample consistent of 67 males and 162 females. A
statistically significant difference was found between the
total CSI-FI scores in the chronic pain and control sam-
ples (p < 0.001). Mean age was also significantly different
between these two subject groups (40.2 ± 10.6 years vs.
45.5 ± 11.8 years respectively; p-value .01). Other demo-
graphics of gender (male/female ratio; 54/133 vs. 13/29),
height (171.2 ± 9.6 vs. 171.3 ± 8.2 cm), weight (75.1 ± 17.1
vs. 76.5 ± 15.9 kg), and body mass index (25.5 ± 4.9 vs.
26.0 ± 4.8 kg/m2) showed no significant differences be-
tween the two subject groups.
Reliability
Internal consistency (Cronbach’s alpha) was good
(0.884 and ICC 0.838; 95% CI 0.792–0.872) and test-
retest reliability of Intraclass correlation coefficient
(ICC) was excellent (0.933 and ICC 0.911; 95% CI
0.882–0.935). Standard error measurement (SEM) was
calculated as 0.425.
Single item ICC was substantial-to-excellent on all
items except item number six (I need help in performing
my daily activities), which was moderate. Table 1. pre-
sents single item ICC and lower and upper bound confi-
dence intervals (CI).
Pain subgroup differences
The comparison of three pain subgroups on subject-
reported clinical variables is presented in Table 2. On
some variables, including the RMDQ and PSQ-3, the
control group scored lowest, the localized pain group
scored in the middle, and the multisite pain group
scored the highest. The control group and localized pain
group were statistically similarly but scored significantly
lower than the multisite pain group on the CSI, EQ-
5D-5L, and dizziness symptoms. Both pain groups
were statistically similar, but scored higher on the
TSK than the control group. In regards to pain-
specific variables, the multisite pain group reported
significantly more chronic low back pain, other mus-
culoskeletal pain, and chronic headaches and longer
pain duration than the localized pain group. There
was no statistical difference in pain severity between
the two pain groups.
Number of subject-reported diagnoses on CSI part B
As shown in Table 3, the total number of CS-related
diagnoses reported in the control group was statistically
different among the three subject groups. Though there
was a clear trend for the multi-site pain group to report
the most individual CSSs and the control group to
report the least, only irritable bowel syndrome was sta-
tistically significant. The most prevalent CSS diagnosis
reported in our sample was depression (N = 56).
Factor analysis
Values of the Kaiser-Meyer-Olkin measure (0.870) and
Bartlett’s Test pf Sphericity (p < 0.001) indicated that a
factor analysis was appropriate for this study sample.
The exploratory factor analysis (EFA) factor 1 explained
28.1% (Eigenvalue 7.026) and factor 2 explained 34.9%
(1.706) of the total variance. A scree plot with eigen-
values is shown in Fig. 2.
Results of the Exploratory Factor Analysis are pre-
sented in Table 4. The ratio of factor 1 Eigenvalue
(7.026) and factor 2 Eigenvalue (1.706) were 4.12, which
met ≥4 requirement for a one factor model [52]. All
items had a required factor loading ≥0.3. Additionally,
recommendation for suitability for factor analysis of at
least five subjects per item were met [53, 54]. A total of
229 subjects and 25 items added up to 9.2 subjects per
item. Factor loading descriptive statistics and factor
loading for each question are presented on the Table 4.
Convergent validity of the CSI-FI
As shown in Table 5, fair to good correlations were
found between the CSI-FI and the Tampa scale of kine-
siophobia, the Depression Scale, 5-level EQ-5D version,
Roland-Morris Disability Questionnaire, and Pain and
Sleep Questionnaire Three-Item Index.
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Small correlations were found between the CSI-FI
score and chronic low back pain. Fair correlations were
found between CSI-FI and pain referral to the leg, other
chronic musculoskeletal pain, numerical pain rating scale,
pain duration, chronic headache and dizziness during
last 12 months.
Small correlations were found between the CSI-FI and
subject-reported fibromyalgia and temporomandibular
joint disorder, and fair correlations were found with mi-
graine or tension type headaches, irritable bowel syn-
drome and depression.
CFI-FI and postural control
Subgroup comparisons among the chronic pain subjects
by CSI-FI cut off scores ≥40 on postural control parame-
ters are presented in Table 6. No significant differences
were found between the two subject groups in age, gen-
der, height, weight, or body mass index. No statistical
differences were measured between the subject groups
in the eight clinical postural tests, although the “Eyes
closed on unstable surface velocity of COP” test
approached significance.
Discussion
Comparing CSI scores across study populations is very
difficult due to the considerable heterogeneity of the dif-
ferent validation cohorts and study reporting practices.
A recent study in Spain, with a similar chronic musculo-
skeletal pain cohort as ours, found a lower mean total
CSI score of 24.6 compared to 37.0 in our sample [55].
The Spanish study did not separate subjects with single
and multiple pain sites and had considerably fewer fe-
males (44.3%) than our study (71.7%), which might ex-
plain to some extent their lower mean total CSI score.
Multiple pain sites is one of the main clinical hallmarks
of the central sensitization and female gender is one the
main risk factors for development of central
sensitization-related chronic pain [1–3]. In other
Table 1 Internal consistency – Cronbach’s alpha, intraclass correlation coefficient (ICC) 95% Confidence Interval (Lower-Upper
Bound) of test-retest reliability
Item ICC CI Lower-Upper
Bound
1 I feel tired and unrefreshed when I wake from sleeping. 0.745 0.643–0.821
2 My muscles feel stiff and achy. 0.725 0.617–0.806
3 I have anxiety attacks. 0.794 0.708–0.856
4 I grind or clench my teeth. 0.895 0.848–0.928
5 I have problems with diarrhea and/or constipation. 0.759 0.661–0.831
6 I need help in performing my daily activities. 0.518 0.358–0.648
7 I am sensitive to bright lights. 0.739 0.635–0.817
8 I get tired very easily when I am physically active. 0.821 0.745–0.876
9 I feel pain all over my body. 0.761 0.664–0.832
10 I have headaches. 0.756 0.658–0.829
11 I feel discomfort in my bladder and/or burning when I urinate. 0.783 0.693–0.848
12 I do not sleep well. 0.795 0.709–0.857
13 I have difficulty concentrating. 0.723 0.614–0.805
14 I have skin problems such as dryness, itchiness or rashes. 0.849 0.784–0.896
15 Stress makes my physical symptoms get worse. 0.723 0.615–0.805
16 I feel sad or depressed. 0.763 0.667–0.834
17 I have low energy. 0.695 0.579–0.784
18 I have muscle tension in my neck and shoulders. 0.813 0.735–0.871
19 I have pain in my jaw. 0.868 0.810–0.909
20 Certain smells, such as perfumes, make me feel dizzy and nauseated. 0.860 0.799–0.904
21 I have to urinate frequently. 0.844 0.875–0.943
22 My legs feel uncomfortable and restless when I am trying to go
to sleep at night.
0.819 0.743–0.875
23 I have difficulty remembering things. 0.815 0.736–0.871
24 I suffered trauma as a child. 0.897 0.851–0.929
25 I have pain in my pelvic area. 0.828 0.754–0.881
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validation studies, CSI scores with adult chronic pain
populations have ranged between 21.9. and 52.4 [18, 20,
24, 26–28, 30]. Cultural differences in symptom-
reporting, differences in the clinical make-up of the
study samples (e.g. gender ratios, chronicity of different
pain syndromes) and reporting practices of different
studies (e.g. different methods of subgrouping subjects),
health history comorbidities (e.g. mental disorders, pre-
vious injuries affecting the central nervous system), and
even genetic differences in different country populations
might help explain the variation in total CSI scores.
The CSI-FI reliability (Internal consistency = 0.884 and
test-retest reliability = 0.933) were very similar to previ-
ous validations, where the range of Cronbach’s alpha has
varied from 0.88 to 0.99 and the range of test-retest has
varied from 0.85 to 0.99 [27, 28, 32]. Though this was
the first CSI-validation which used a digital data collec-
tion format, we found similar reliability results to previ-
ous traditional paper format data collection formats.
Test-retest ICC lower and upper bound were excellent,
in spite of CSI question 6 (I need help in performing my
daily activities), which showed somewhat lower substan-
tial reliability.
SEM values assess the likelihood of a “true” score,
which represent a reliable score without any fluctuations
from systematic and random factors related to the meas-
urement process. The general rule for interpreting re-
sults is that lower scores indicate higher reliability and
more confidence that the score has been measured ac-
curately. In the present study, SEM was 0.42, which indi-
cated that the CSI-FI scores were close to the “true”
score. In previous validations, only the Nepali CSI
Table 2 Subject-reported clinical variables among three subgroups (N = 229)
Pain free control
group (N = 42)
Chronic pain in a
single body area
(N = 79)
Multisite pain (two or
more chronic pain




Yes No Yes No Yes No χ2 χ2
Chronic low back pain 0 (0%) 42 (100%) 56 (71%) 23 (29%) 105 (97%) 3 (3%) < 0.001* a (< 0.001*)
b (< 0.001*)
c (< 0.001*)
Referral to leg or leg pain (if chronic l
ow back pain was indicated)
0 (0%) 42 (100%) 28 (35%) 51 (65%) 59 (55%) 49 (45%) < 0.001* a (< 0.001*)
b (< 0.001*)
Other chronic musculoskeletal pain 0 (0%) 42 (100%) 23 (29%) 56 (71%) 106
(98%)
2 (2%) < 0.001* a (< 0.001*)
b (< 0.001*)
c (< 0.001*)
Subject reported Chronic headache 0 (0%) 42 (100%) 0 (0%) 71 (100%) 24 (22%) 84 (78%) < 0.001* b (< 0.001*)
c (< 0.001*)
Previous Rheumatic disease diagnosis 0 (0%) 42 (100%) 2 (2%) 77 (98%) 8 (7%) 100 (93%) 0.84
Dizziness during last 12 months 4 (10%) 38 (90%) 9 (11%) 70 (89%) 40 (37%) 68 (63%) < 0.001* b (< 0.001*)
c (< 0.001*)
One-Way ANOVA Post hoc LSD
Numerical pain scale 0 ± 0 3.8 ± 2.8 4.7 ± 2.1 < 0.001* a (< 0.001*)
b (< 0.001*)
Pain in months 0 ± 0 39.7 ± 6.9 76.7 ± 83.7 < 0.001* a (0.04*)
b (< 0.001*)
c (< 0.001*)
CSI score 28.0 ± 10.7 31.8 ± 10.1 40.7 ± 11.7 < 0.001* b (< 0.001*)
c (< 0.001*)
TSK 25.8 ± 4.9 30.2 ± 6.8 33.0 ± 7.7 < 0.001* a (0.01*)
b (< 0.001*)
DEPS 5.4 ± 4.3 4.8 ± 3.9 7.3 ± 5.4 0.01* c (< 0.001*)
RMDQ 0.4 ± 0.9 2.6 ± 3.1 4.4 ± 3.7 < 0.001* a (< 0.001*)
b (< 0.001*)
c (< 0.001*)
PSQ-3 2.0 ± 3.6 6.2 ± 6.6 9.3 ± 7.4 < 0.001* a (0.01*)
b (< 0.001*)
c (0.01*)
EQ-5D-5L 0.85 ± 0.097 0.79 ± 0.079 0.74 ± 0.129 0.01* b (< 0.001*)
c (0.01*)
One-Way ANOVA post hoc comparison of Fisher’s Least Significant Difference (LSD). Statistical significance p < 0.05*. Comparison between control group without
pain and single body area pain (a), between control group without pain and multisite pain (b), and between single body area pain and multisite pain (c)
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reported a smaller SEM (0.31) score [28]. In other
CSI validations, SEM scores have ranged from 1.84 to
3.16 [21, 23, 24, 27].
A previous factor analysis (EFA with maximum likeli-
hood extraction) in a large pooled multicountry sample
yielded a bifactor solution, in which one general “CS-re-
lated symptoms” factor showing “substantial reliability.”
Four subfactors were clearly identified, but their reliabil-
ity was not sufficient enough to be recommended for
use as individual subscales in research or clinical work
[8]. Because of this recommendation, CSI subscales were
not used in the present study. Our data met the same re-
quirements as the multicountry study, although our fac-
tor loading was set at 0.3 instead of 0.4. Two items in
our sample, 4 and 25, loaded between 0.3 and 0.4, so the
correlation coefficients were somewhat weaker com-
pared to the multicountry sample. Additionally, in our
sample, factor 1 explained 28.1% of the variance,
whereas in multinational sample, factor 1 explained
36.1% of the variance. Hence, the percentage of ex-
plained variance was somewhat lower in our study.
However, in previous Spanish [21] and Italian [30]
Table 3 Number of subject-reported diagnoses on CSI part B by three subject subgroups (N = 229)
CSS diagnoses N Control group
without pain (N = 42)
Single body area







1 Restless Leg Syndrome 5 0 3 (60%) 2 (40%) 0.376
2 Chronic Fatigue Syndrome 1 0 0 1 (100%) 0.570
3 Fibromyalgia 5 0 2 (40%) 3 (60%) 0.560
4 Temporomandibular Joint Disorder
(TMJ)
32 6 (18.8%) 7 (21.9%) 19 (59.4%) 0.235
5 Migraine or tension headaches 35 3 (8.6%) 12 (34.3%) 20 (57.1%) 0.221
6 Irritable Bowel Syndrome 35 1 (2.9%) 6 (17.1%) 28 (80%) <0.001* b (0.01*)
c (0.01*)
7 Multiple Chemical Sensitivities 7 1 (14.3%) 1 (14.3%) 5 (71.4%) 0.402
8 Neck Injury (including whiplash) 17 0 (0%) 6 (34.5%) 11 (64.7%) 0.102
9 Anxiety or Panic Attacks 29 6 (20.7%) 7 (24.1%) 16 (55.2%) 0.453




Total number of CSS diagnoses 222 23 (10.4%) 61 (27.5%) 138 (62.1%) <0.001* b (<0.001*)
c (0.005*)
Pearson Chi-Square (χ2), statistical significance p < 0.05*. Comparison between control group without pain and single body area pain (a), between control group
without pain and multisite pain (b), and between single body area pain and multisite pain (c). Total number of CSS diagnoses Kruskal-Wallis Test and Mann-
Whitney Test, statistical significance p < 0.05*
Fig. 2 Scree plot of factor analysis
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validations, which also yielded 1 factor model solutions,
factor 1 explained only 25.9 and 26% of the variance, re-
spectively, which are lower than in the present valid-
ation. It should be noted that the multicountry CSI
study had a much larger study cohort (n = 1987) and
more heterogeneous sample of subjects than other valid-
ation studies, including ours, which may explain some
differences in the results.
Fair correlations (0.25 > Rs ≤ 0.50) were found between
the CSI-FI and other subject-reported variables, includ-
ing the TSK (kinesiophobia), RMDQ (disability) pain
history questions of pain referral to leg, other chronic
musculoskeletal pain, numerical pain rating scale, pain
duration in months, chronic headache, and dizziness in
last 12 months. Moderate-to-good correlations were
found between the CSI-FI and the DEPS (depression),
PSQ-3 (impact of pain on sleep) (0.50 > Rs2 ≤ 0.75) and
negatively moderately-to-good correlations were found
with the EQ-5D-5L (quality of life). The correlation be-
tween CSI-FI scores and subject-reported chronic low
back pain was not significant. Pain history findings are
difficult to compare to previous validations because of
the heterogeneity of study samples, data collection
methods, and collection of clinical variables that are not
standardised as in PROMs. In one previous validation,
the TSK was studied in an adolescent population [31]
and EQ-5D-5L [26] and RMDQ [30] in an adult popula-
tion [26], which showed similar correlations with the
CSI. The relationship between the CSI-FI and the
patient-reported outcome measures in the present study
provide additional evidence of the convergent validity of
the CSI.
The total subject sample was divided into 3 subject
groups for discriminative analysis, including a pain-free
group, localized chronic pain group, and multi-site
chronic pain group. It was assumed that the multisite
chronic pain group would likely have the most CS and
the control group the least amount of CS among the
groups. In fact, the multisite pain group reported the
highest number of CSSs, and the control group reported
the lowest number of CSSs, on CSI part B. In addition
to more widespread pain, the multi-site pain group
Table 4 Exploratory Factor Analysis one factor model
CSI Items Mean SD Factor loading
1 I feel tired and unrefreshed when I wake from sleeping. 2.24 .84 .50
2 My muscles feel stiff and achy. 2.38 .83 .49
3 I have anxiety attacks. 1.03 .94 .58
4 I grind or clench my teeth. 1.19 1.12 .32
5 I have problems with diarrhea and/or constipation. 1.51 .93 .43
6 I need help in performing my daily activities. .25 .53 .43
7 I am sensitive to bright lights. 1.24 1.16 .46
8 I get tired very easily when I am physically active. 1.38 1.00 .60
9 I feel pain all over my body. .75 .94 .56
10 I have headaches. 1.42 .81 .50
11 I feel discomfort in my bladder and/or burning when I urinate. 0.36 .70 .40
12 I do not sleep well. 1.98 0.92 .50
13 I have difficulty concentrating. 1.66 .83 .58
14 I have skin problems such as dryness, itchiness,or rashes. 1.52 1.07 .48
15 Stress makes my physical symptoms get worse. 2.14 1.06 .64
16 I feel sad or depressed. 1.42 .79 .56
17 I have low energy. 1.88 .77 .64
18 I have muscle tension in my neck and shoulders. 2.36 .95 .60
19 I have pain in my jaw. .88 1.01 .53
20 Certain smells, such as perfumes, make me feel dizzy and nauseated. .97 1.17 .49
21 I have to urinate frequently. 1.54 1.14 .43
22 My legs feel uncomfortable and restless when I am trying to go to sleep at night. .93 0.99 .42
23 I have difficulty remembering things. 1.51 .86 .52
24 I suffered trauma as a child. .96 1.16 .42
25 I have pain in my pelvic area. 2.10 1.18 .30
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reported significantly more perceived level of disability,
depressive symptoms, perceived level of disability, poorer
quality of life, pain-related sleep problems, chronic head-
aches, and longer pain duration than the localized pain
group. Compared to the localized pain group, the multi-
site group scored significantly higher on the CSI-FI. As-
sociations have been found between CSI scores and
similar symptom reporting in other previous studies [27,
33, 34]. The results of the present study provide further
evidence of discriminant validity of the CSI.
The relationship between CSI scores and subjective
symptoms of dizziness has not been studied previously.
Dizziness is a common symptom with many possible
underlying causes, but it is not an actual diagnosis point-
ing into one specific cause of dizziness [56]. Subjective
dizziness symptoms were divided in six different sub-
types in the present study, pointing to different possible
proprioceptive, visual, and/or vestibular dizziness diag-
noses. Interestingly, significantly more patients in our
multi-site chronic pain group, which is very well-known
hallmarks of central sensitivity [1, 2] reported dizziness
(37%) comparing to both the localized chronic pain
group (11%) and the pain-free control group (10%). Fur-
thermore, dizziness correlated better with the CSI-FI
than most of the pain symptoms (chronic low back pain,
pain referral to leg, numerical pain rating scale, pain
duration in months and chronic headache) or any of the
CSS diagnoses on CSI part B. It was known from previ-
ous studies that dizziness is a common symptom in pa-
tients with a fibromyalgia diagnosis [15–17]. We were
unable to fully assess the relationship between dizziness
and fibromyalgia in the present study population be-
cause only five subjects had a fibromyalgia diagnosis.
However, the relatively high prevalence of dizziness
symptom in our multisite pain group, and the relation-
ship between dizziness symptoms and total CSI-FI
scores, suggests that further research on this topic is
warranted.
Some previous studies (but not all) have demonstrated
associations between CSI scores and objective measures of
central sensitization, including chemical measurements of
Table 5 Correlations between total CSI-FI scores and subject-





Tampa Scale of Kinesiophobia (TSK) 0.463*
Depression Scale (DEPS) 0.615**
The Roland-Morris Disability Questionnaire
(RMDQ)
0.387*
The Pain and Sleep Questionnaire Three-Item
Index (PSQ-3),
0.505**
EuroQol The 5-level EQ-5D version (EQ-5D-5L) −0.554**
Pain and dizziness history
Chronic low back pain 0.245
Pain referral to leg 0.291*
Other chronic musculoskeletal pain 0.425*
Numerical Pain Rating Scale (NPRS) 0.290*
Pain duration in months 0.253*
Chronic headache 0.255*
Dizziness in the last 12 months 0.323*
CSS Number of subject-reported diagnoses on CSI part B
1 Restless Leg Syndrome 0.055
2 Chronic Fatigue Syndrome 0.101
3 Fibromyalgia 0.142
4 Temporomandibular Joint Disorder (TMJ) 0.223
5 Migraine or tension headaches 0.295*
6 Irritable Bowel Syndrome 0.296*
7 Multiple Chemical Sensitivities 0.163
8 Neck Injury (including whiplash) 0.066
9 Anxiety or Panic Attacks 0.163
10 Depression 0.305*
Little or no correlation (<0.25), Fair correlation (0.25 > Rs ≤ 0.50) *, moderate to
good correlation (0.50 > Rs2 ≤ 0.75) **
Table 6 Postural control on force plate on groups of recommended CSI cut off score ≥ 40 on subjects with chronic pain (n = 187)
Test on force plate CSI ≤39 group (N = 117) mean ± SD CSI ≥40 group (N = 70) mean ± SD p- value
Eyes open on firm surface area of COP [mm2] 296.4 ± 164.0 274 ± 161.8 0.32
Eyes open on firm surface velocity of COP [mm/s] 9.7 ± 3.0 9.3 ± 2.8 0.40
Eyes closed on firm surface area of COP [mm2] 464.1 ± 356.8 433.2 ± 362.7 0.28
Eyes closed on firm surface velocity of COP [mm/s] 15.8 ± 7.7 14.5 ± 5.7 0.31
Eyes open on unstable surface area of COP [mm2] 510.0 ± 251.0 466.4 ± 244.0 0.24
Eyes open on unstable surface velocity of COP [mm/s] 14.6 ± 4.3 14.1 ± 3.6 0.54
Eyes closed on unstable surface area of COP [mm2] 1142.2 ± 641.0 1028.6 ± 544.4 0.20
Eyes closed on unstable surface velocity of COP [mm/s] 31.0 ± 11.4 28.0 ± 9.8 0.06
Mann-Whitney Test, statistical significance p < 0.05*
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brain derived neurotrophic factor [22], gamma aminobu-
tyric levels [57], and a cold-pressure conditioned pain
modulation test [22]. We hypothesized a relationship be-
tween higher CSI scores and poorer postural control test
results on a force plate. Previous studies have shown dif-
ferences in postural control between patients with a fibro-
myalgia diagnosis and pain-free controls, especially when
visual information was missing [58]. We assessed COP
and velocity COP because they have been the most com-
monly used parameters in previous research on low back
pain populations [36, 49]. The postural stability testing
was carried out with two groups with significantly differ-
ent CSI scores, but no significant demographic differences
on age, gender, height, weight or body mass index, and an
appropriate and detailed test protocol with an adequate
sample size. Two out of four tests were carried out with
eyes closed to assess the impact of missing visual informa-
tion. However, our study failed to show a relationship be-
tween higher CSI-FI scores and poorer postural control.
Strengths and limitations
Strengths
Some strengths of this study included a very thorough val-
idation of different measurement properties of the CSI-FI,
including cross-cultural validity, face validity, internal
consistency, test-retest reliability, measurement error, dis-
criminant validity, structural validity, and convergent
validity with an adequate subject cohort size. Furthermore,
two novel measurements were assessed in relation to CSI-
FI scores, including state-of-the-art postural control test-
ing and subjective symptoms of dizziness.
Limitations
As with other studies of this kind, the results are based
on one subject sample in a single clinic, so
generalization to other subject populations should be
made with caution. All symptoms were self-reported,
and pain reporting was limited by the items on a single
questionnaire. Actual medical diagnoses by a trained
clinician were lacking. However, the self-reported data
from our subject sample showed no discrepancies or il-
logical patterns of answers to suggest that they were in-
valid or had any considerable negative effects on our
findings. Furthermore, it can also be noted that muscu-
loskeletal pain symptoms and clinical diagnoses were
primarily determined by subject self-report and not by
trained clinicians [59]. The study advertisement specified
“force plate measurements, personal feedback, and stan-
dardised exercises,” so we might have attracted subjects
with balance problems, which may have explained a sur-
prisingly high proportion of subject-reported dizziness
symptoms. The study clinic also specializes in treatment
of balance impairments, which might have encouraged
more subjects with balance problems and dizziness to
volunteer for the study. Hypothesis testing was not car-
ried out, which is recommended on the COSMIN check-
list because we felt it would not add any validity to the
successful validation of the CSI-FI.
Suggestions for further research
CSI part B is limited to 7 CSSs and 3 related diagnoses.
Additional CSSs and related symptoms (such as dizzi-
ness) could be added to CSI part B data collection and
studied along with total CSI scores. This might help
clinical symptom-based sub-classification of different
CSS syndromes and hence developing more specific
treatment for different CSS syndromes. Based on the re-
sults of the current study, additional research on the re-
lationship of dizziness and CSI scores is warranted.
Possibly subtype of CS-related dizziness and targeted
treatment protocols for dizziness could be developed.
The wide range of average CSI mean scores across dif-
ferent CSI validation studies needs further elaboration -
maybe a review-type study comparing similarities and
differences of different CSI validations in different sub-
ject populations.
Conclusions
The CSI was successfully cross-culturally adapted and
validated into Finnish. The psychometric properties of
internal consistency, test-retest reliability, measurement
error, content validity, convergent validity, and discrim-
inative validity were all found to be acceptable and in
line with previous successful CSI validations. The CSI-FI
may be a useful screening tool for assessing CS/CSS-re-
lated symptoms in clinical and research populations
among Finnish speaking patients.
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